Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Design

Volume 16 Issue 14
ISSN: 1381-6128
eISSN: 1873-4286


   All Titles

  Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
  pp.1561-1567 (7) Authors: Maarten Brom, Karolina Andraojc, Wim J.G. Oyen, Otto C. Boerman, Martin Gotthardt

The changes in beta-cell mass (BCM) during the course of diabetes are not yet well characterized. A non-invasive method to measure the BCM in vivo would allow us to study the BCM during the onset and progression of the diseases caused by beta-cell dysfunction. PET and SPECT imaging are attractive approaches to determine the BCM because of their high sensitivity and the possibility to quantitatively analyze the images. Several targets and their corresponding radiotracers have been examined for their ability to determine the BCM including radiolabeled antibodies, antibody fragments, peptides and small molecules. Although some of these tracers show promising results, there is still no reliable method to determine the beta-cell mass in vivo. In this review, the targets and the corresponding radiotracers evaluated so far for the determination of the BCM in vivo in humans will be discussed.

  Keywords: Beta-cell mass, radiotracers, peptides, antibodies, nuclear medicine, imaging
  Affiliation: Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers